Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Chunghwa Chemical Synthesis & Biotech Co Forward PE Ratio Related Terms
Chunghwa Chemical Synthesis & Biotech Co Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chunghwa Chemical Synthesis & Biotech Co Forward PE Ratio Chart
Chunghwa Chemical Synthesis & Biotech Co Annual Data
Trend
2025-12
Forward PE Ratio
54.78
Chunghwa Chemical Synthesis & Biotech Co Quarterly Data
2025-09
2025-12
2026-03
2026-06
Forward PE Ratio
57.78
54.78
65.44
80.56
TPE:1762 vs VRTX, REGN, RVMD: Forward PE Ratio Comparison
For the Biotechnology subindustry, Chunghwa Chemical Synthesis & Biotech Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chunghwa Chemical Synthesis & Biotech Co Forward PE Ratio vs Biotechnology Industry
Chunghwa Chemical Synthesis & Biotech Co Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) has a Forward PE Ratio of 77.89 as of Aug. 17, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. According to the industry distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #284 out of 357 companies in the Biotechnology industry, placing it in the top 79.6%.
Is Chunghwa Chemical Synthesis & Biotech Co's Forward PE Ratio too high?
Chunghwa Chemical Synthesis & Biotech Co's current Forward PE Ratio is 77.89. The Biotechnology industry median Forward PE Ratio is 23.03. Chunghwa Chemical Synthesis & Biotech Co's value of 77.89 is 238.2% above this industry median. Based on the distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #284 out of 357 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chunghwa Chemical Synthesis & Biotech Co has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chunghwa Chemical Synthesis & Biotech Co's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #284 out of 357 companies for Forward PE Ratio. This places Chunghwa Chemical Synthesis & Biotech Co in the lower half of its industry. The industry median Forward PE Ratio is 23.03. Chunghwa Chemical Synthesis & Biotech Co's value of 77.89 is 238.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 23.03, based on 357 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chunghwa Chemical Synthesis & Biotech Co's current Forward PE Ratio of 77.89 is 238.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 23.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chunghwa Chemical Synthesis & Biotech Co's current Forward PE Ratio is 77.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chunghwa Chemical Synthesis & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$40.11, compared to a current price of NT$35.00 — trading 12.7% below its estimated fair value. The current Forward PE Ratio is 77.89 and 238.2% above the Biotechnology industry median of 23.03. Chunghwa Chemical Synthesis & Biotech Co's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Chunghwa Chemical Synthesis & Biotech Co (TPE:1762), the current Forward PE Ratio is 77.89 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) Overvalued in 2026?
Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co stock appears to be undervalued.
The current stock price of NT$35.00 is trading 12.7% below its estimated GF Value™ of NT$40.11.
GuruFocus considers Chunghwa Chemical Synthesis & Biotech Co to be Modestly Undervalued.
Key valuation signals for TPE:1762:
Forward PE Ratio: 77.89
GF Value™: NT$40.11 vs. price of NT$35.00 (12.7% below fair value)
Industry Position: 238.2% above the Biotechnology median (#284 of 357)
No single metric tells the full story. See the TPE:1762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chunghwa Chemical Synthesis & Biotech Co Ltd is engaged in the research, development, manufacturing, and sales of pharmaceutical products. Geographically, it derives a majority of its revenue from the United States and also has a presence in Taiwan. Its product portfolio comprises pain management, antifungal, immunosuppressant, oncology, Cardiovascular, Peptide Drugs, and Others.
60GF Score
Get the complete analysis for TPE:1762
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1762 has been successfully added to your 
